GCBiopharma will diversify its vaccine production bases. The strategy is to lower reliance on specific production facilities to respond to domestic and overseas supply chain risks, while also securing a production base in advance for a next-generation influenza vaccine under development.

GC Biopharma said on the 10th that it signed a memorandum of understanding (MOU) with KOREAVACCINE to cooperate on contract manufacturing organization (CMO) business for vaccines. The signing ceremony was held on the 9th at KOREAVACCINE's headquarters in Ansan, Gyeonggi.

The two companies plan to cooperate across contract manufacturing of vaccines in prefilled syringe (PFS) form.

(From left) Shin Ung, GC Biopharma head of operations, and Park Hong-gyo, KOREAVACCINE bioplant factory manager, sign a memorandum of understanding for mutual cooperation on the 9th and pose for a commemorative photo./Courtesy of GC Biopharma

With this agreement, GC Biopharma has expanded the finished drug production base for its influenza vaccine "GC Flu." The company also plans to establish in advance a production system for a high-immunogenicity (high-antigen dose) influenza vaccine under development. The company is pushing development with the goal of obtaining marketing authorization within the next three years.

GC Biopharma expects the collaboration to also help rapidly secure vaccine manufacturing capacity in future public health emergencies such as pandemics. KOREAVACCINE is equipped with production facilities that meet the standards of the World Health Organization (WHO) prequalification (PQ) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

※ This article has been translated by AI. Share your feedback here.